Ganapathy Sivakumar has extensively studied the plant-based small molecules pathway biochemistry, synthetic biotechnology and metabolic & bioprocess engineering. His research is primarily focused on biomanufacturing and biotech implications of biopharmaceuticals. He is internationally recognized in the field of
Biopharmaceuticals and a pioneer in biomanufacturing of biorhizome-based colchicine. He has over 45 publications. He is also on the Editorial Board of several journals. He serves as an expert of grant proposals as well as numerous scientific journals. His laboratory focuses on metabolic and bioprocess engineering of
colchicine pathway and developing potential anticancer medicine
Many human medicines are biomanufactured by recombinant DNA technology. Colchicine is one of the potential plantbased alkaloid medicines used to treat gout, which is commercially extracted from Gloriosa superba. My laboratory is establishing the biorhizome-based colchicine biomanufacturing technology to produce the drugs. G. superba-based biorhizomes are unique and efficient colchicine biosynthetic mechanisms, which is an advanced biotechnological platform compared to root and cell cultures. Colchicine from biorhizomes could lower upstream biomanufacturing costs, speed production and reduce pesticide contamination. Metabolic engineering of colchicine biosynthetic pathway in biorhizome requires detailed pathway elucidation. The biorhizome-based colchicine biomanufacturing and colchicine pathway elucidation will be presented.